参萸养胃汤联合FOLFOX4方案治疗中晚期胃癌临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.2

基金项目:


Clinical Study on Treatment of Middle-Advanced Stage Gastric Cancer with Shenyu Yangwei Decoction Combined with FOLFOX4 Regimen
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察参萸养胃汤联合奥沙利铂、亚叶酸钙、5-氟尿嘧啶(FOLFOX4)化疗方案治疗中晚期 胃癌的效果。方法:选取2022年6月—2024年6月南阳医学高等专科学校第一附属医院120例中晚期胃癌患 者,按随机数字表法分为对照组和观察组各60例。对照组采用FOLFOX4方案化疗,观察组在对照组的基础上 加服参萸养胃汤。治疗8周后,比较2组治疗前后中医证候评分、免疫功能指标水平;评估2组临床疗效,并 记录治疗期间2组化疗毒副反应分级情况。结果:观察组客观缓解率为61.67%(37/60)、疾病控制率为90.00% (54/60),对照组分别为35.00%(21/60)、75.00%(45/60),2组比较,差异均有统计学意义(P<0.05)。治疗 后,2组中医证候评分均较治疗前降低(P<0.05),且观察组评分低于对照组(P<0.05)。治疗后,2组CD3 + 、 CD4 + 、CD4 + /CD8 + 水平均较治疗前降低 (P<0.05),但观察组上述指标水平均高于对照组 (P<0.05)。治疗期 间,观察组恶心、呕吐、白细胞减少、血小板减少等毒副反应分级程度均低于对照组(P<0.05)。结论:参萸 养胃汤联合FOLFOX4方案治疗中晚期胃癌可提高临床疗效,改善中医证候,减轻化疗对免疫功能的影响,减 少化疗毒副反应。

    Abstract:

    Abstract: Objective: To observe the efficacy of Shenyu Yangwei Decoction combined with oxaliplatin, leucovorin,and 5-fluorouracil(FOLFOX4)chemotherapy regimen in treating middle-advanced stage gastric cancer. Methods:A total of 120 patients with middle-advanced stage gastric cancer treated at the First Affiliated Hospital of Nanyang Medical College from June 2022 to June 2024 were selected and divided into a control group and an observation group,with 60 cases in each group,using a random number table method. The control group received FOLFOX4 chemotherapy,while the observation group additionally took Shenyu Yangwei Decoction on the basis of the control group. After eight weeks of treatment,the traditional Chinese medicine syndrome scores and immune function index level were compared between the two groups before and after treatment. Clinical efficacy was assessed, and the classification of chemotherapy-related toxic and adverse reactions during treatment was recorded. Results: The objective response rate in the observation group was 61.67%(37/60)and the disease control rate was 90.00%(54/60), compared to 35.00%(21/60)and 75.00%(45/60)in the control group,respectively,with significant differences between the two groups(P<0.05). After treatment,the traditional Chinese medicine syndrome scores in both groups were decreased compared to before treatment(P<0.05),with the observation group achieving lower scores than the control group(P<0.05). The levels of CD3 + ,CD4 + ,and CD4 + /CD8 + in both groups were decreased compared to before treatment(P<0.05),with the observation group achieving higher levels than the control group(P<0.05). During treatment,the observation group had lower grades of toxic and adverse reactions such as nausea,vomiting,leukopenia and thrombocytopenia compared to the control group(P<0.05). Conclusion:Shenyu Yangwei Decoction combined with the FOLFOX4 regimen can improve clinical efficacy and the traditional Chinese medicine syndromes in treating middle-advanced stage gastric cancer, reduce the impact of chemotherapy on immune function, and alleviate chemotherapy-related toxic and adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

徐艳琴,付静娅,高雷,李晓棠,亚国伟,李凡.参萸养胃汤联合FOLFOX4方案治疗中晚期胃癌临床研究[J].新中医,2025,57(16):126-130

复制
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-08-26
  • 出版日期:
文章二维码